TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21697747

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Concurrent Training (CT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control
Number of subjects: 47
Study: 20956620

Group type: EXPERIMENTAL
Intervention: RT + CON
Number of subjects: 333

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 333
Study: 18976980

Group type: EXPERIMENTAL
Intervention: Highly structured training method (18-step approach)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional training method (9-step approach)
Number of subjects: 16
Study: 15750868

Group type: EXPERIMENTAL
Intervention: Consistent mapping (CM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Varied mapping (VM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed-task blocks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task-switch trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pure and mixed tasks (between-participants)
Number of subjects: 0
Study: 12492263

Group type: EXPERIMENTAL
Intervention: Structured motivational enhancement program
Number of subjects: 64
Study: 10323159

Group type: EXPERIMENTAL
Intervention: Two coats of a copal varnish
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: A dentin adhesive resin liner
Number of subjects: 76

Group type: COMPARATOR
Intervention: No liner
Number of subjects: 76

Group type: COMPARATOR
Intervention: A resin‐modified glass‐ionomer liner
Number of subjects: 76
Study: 8955549

Group type: EXPERIMENTAL
Intervention: Training procedure to improve Wisconsin Card Sorting Test performance
Number of subjects: 10

Group type: COMPARATOR
Intervention: No monetary incentive
Number of subjects: 10
Study: 1657799

Group type: EXPERIMENTAL
Intervention: Intravenous enalaprilat (0.2-1.2 mg, mean 1.0 mg) administered as bolus to 20 patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intravenous enalaprilat (1 mg) administered as infusion over two hours to 20 patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intravenous enalaprilat (1 mg) administered as infusion over two hours to 8 patients with systolic blood pressure between 100-109 mmHg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intravenous enalaprilat
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oral enalapril (2.5-10 mg/day) continued after intravenous treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional therapy (thrombolytic treatment, intravenous metoprolol, intravenous nitroglycerin, intravenous furosemide)
Number of subjects: 48
Study: 7041943

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (CP) immunotherapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 92
Study: 31368770

Group type: EXPERIMENTAL
Intervention: d-cycloserine (50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-cycloserine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contingency management
Number of subjects: 0
Study: 31603565

Group type: EXPERIMENTAL
Intervention: Moderate chronic kidney disease (CKD) patients
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Self-reported awareness of periodontal conditions
Number of subjects: 270
Study: 28419106

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control facilities
Number of subjects: 16
Study: 26787012

Group type: EXPERIMENTAL
Intervention: Individual Valgus Correction Angle (VCA)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Fixed Valgus Correction Angle (VCA)
Number of subjects: 133
Study: 24975467

Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study: 21509432

Group type: EXPERIMENTAL
Intervention: Prepaid cash incentive of $5
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Coupon for diapers valued at $6
Number of subjects: 638

Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 638
Study: 19507140

Group type: EXPERIMENTAL
Intervention: 5% Glutaraldehyde (GD)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 6.5% Grape seed extract (GSE)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.5% Genipin (GE)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 64
Study: 17616862

Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: glimepiride
Number of subjects: 192
Study: 16083704

Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg/day for 1 week)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (1 g/day for 3 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 30
Study: 12219865

Group type: EXPERIMENTAL
Intervention: Manipulated desirability of items that can be purchased with income in Study 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Income enabling purchase of desired items in Study 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparisons with a person's past in Study 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social comparison in Study 3
Number of subjects: 0
Study: 10347293

Group type: EXPERIMENTAL
Intervention: Body temperature CO2 pneumoperitoneum
Number of subjects: 30

Group type: COMPARATOR
Intervention: Room temperature CO2 pneumoperitoneum
Number of subjects: 30
Study: 7577895

Group type: EXPERIMENTAL
Intervention: 60 g textured vegetable protein (TVP)/d, containing 45 mg conjugated isoflavones
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 50 g miso/d, containing 25 mg unconjugated isoflavones
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 28 g TVP/d, containing 23 mg conjugated isoflavones
Number of subjects: 15

Group type: COMPARATOR
Intervention: 60 g of a soyabean product with chemically extracted isoflavones (Arcon F)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 45 mg conjugated isoflavones as 60 g TVP
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 45 mg conjugated isoflavones
Number of subjects: 15

Group type: COMPARATOR
Intervention: 23 mg conjugated isoflavone-free Arcon F
Number of subjects: 15
Study: 1962157

Group type: EXPERIMENTAL
Intervention: Neck school reinforced with compliance enhancing measures (group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional neck school (group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 0
Study: 7062228

Group type: EXPERIMENTAL
Intervention: Telemetry monitoring
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cardiotocography monitoring (Control)
Number of subjects: 60
Study: 31637668

Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg or 250 mg daily for a 4-week cycle)
Number of subjects: 20
Study: 29022390

Group type: COMPARATOR
Intervention: Lactobacillus reuteri DSM 17938 (LR DSM 17938) administered for 105 days, double dosage of 4×10^8 cfu for the first 15 days, followed by standard dosage of 2×10^8 cfu
Number of subjects: 56

Group type: COMPARATOR
Intervention: Lactobacillus reuteri DSM 17938 (LR DSM 17938)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 26688435

Group type: EXPERIMENTAL
Intervention: Emulsion S
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Emulsion N
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oil capsules
Number of subjects: 10
Study: 24724887

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Disulfiram with placebo
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Disulfiram with naltrexone
Number of subjects: 107
Study: 22529026

Group type: EXPERIMENTAL
Intervention: 0.5% moxifloxacin
Number of subjects: 63

Group type: COMPARATOR
Intervention: 0.3% gatifloxacin
Number of subjects: 63

Group type: COMPARATOR
Intervention: 0.5% levofloxacin
Number of subjects: 63
Study: 20831465

Group type: EXPERIMENTAL
Intervention: Knowledge (measured by KASE questionnaire)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Attitude (measured by KASE questionnaire)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Self-efficacy (measured by KASE questionnaire)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Asthma Quality of Life (measured by AQLQ)
Number of subjects: 180
Study: 18483000

Group type: EXPERIMENTAL
Intervention: Ventricular arrhythmia bursts during or subsequent to reperfusion
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Higher absolute peak ST segments and more frequent worsening of ST elevation immediately after reperfusion
Number of subjects: 157
Study: 16229019

Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg b.i.d.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 14607319

Group type: EXPERIMENTAL
Intervention: Fully automated analysis using conventional spin echo (SE) MRI sequence
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Semi-automated analysis
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 2D multi-slice sequences (SE and FLAIR) with fully automated analysis
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo arm of a clinical trial
Number of subjects: 13
Study: 10834685

Group type: EXPERIMENTAL
Intervention: Percutaneous dilational tracheostomy (PDT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional surgical tracheostomy (ST)
Number of subjects: 56
Study: 8557138

Group type: EXPERIMENTAL
Intervention: Danazol 600 mg/d for 2 to 4 weeks (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Leuprolide acetate depot 3.75 mg for 2 months (n = 15)
Number of subjects: 30
Study: 2061442

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% scalp application
Number of subjects: 378

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 378
Study: 6125562

Group type: EXPERIMENTAL
Intervention: Antidepressants alone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combination of antipsychotic and antidepressant medication
Number of subjects: 64
Study: 30856181

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine and midazolam (KMIN)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Oral ketamine and midazolam (KMO)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Oral midazolam (MO)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 84
Study: 28499420

Group type: COMPARATOR
Intervention: Intrathecal morphine (100 mcg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block plus single-shot sciatic nerve block
Number of subjects: 39
Study: 26472133

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (individual counselling sessions on nutrition, physical activity, and weight monitoring)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (routine prenatal care and an information leaflet)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Whole study cohort
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Intervention group infants
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Energy intake and macronutrient composition during pregnancy
Number of subjects: 250
Study: 24716637

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1000 IU/day)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (nonsupplementation)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1000 IU/day) in TT genotype
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (nonsupplementation) in TT genotype
Number of subjects: 84
Study: 22818784

Group type: EXPERIMENTAL
Intervention: Peak exercise cardiac index (CI)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: LV end-diastolic pressure estimates (E/e')
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Tricuspid annular plane systolic excursion (TAPSE)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Peak exercise CI (multivariate analysis)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: E/e' (multivariate analysis)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: TAPSE (multivariate analysis)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: LV ejection fraction at rest
Number of subjects: 102
Study: 19208715

Group type: EXPERIMENTAL
Intervention: Endoscopy performed by doctors
Number of subjects: 1888

Group type: COMPARATOR
Intervention: Endoscopy performed by nurses
Number of subjects: 1888
Study: 18159966

Group type: EXPERIMENTAL
Intervention: Appointment-letter intervention
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (no appointment letter)
Number of subjects: 320
Study: 15110095

Group type: EXPERIMENTAL
Intervention: High dose of PhIP (7.4 ng/g)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Low dose of PhIP (1.7 ng/g)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: CYP1A2 genotype
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: NAT2 genotype
Number of subjects: 71
Study: 11808891

Group type: EXPERIMENTAL
Intervention: Dietary intervention (36 subjects)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Control group (11 subjects)
Number of subjects: 311
Study: 9738129

Group type: EXPERIMENTAL
Intervention: SPLIT (two 15-min sessions, separated by 6 hr)
Number of subjects: 10

Group type: COMPARATOR
Intervention: CONT (30 min of exercise at 70% VO(2)max)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both SPLIT and CONT
Number of subjects: 10
Study: 8056578

Group type: EXPERIMENTAL
Intervention: Azelastine (2 mg) + vitamin C (500 mg) + vitamin E (200 mg) + glutathione (200 mg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (same regimen without Azelastine)
Number of subjects: 63
Study: 3202095

Group type: EXPERIMENTAL
Intervention: Combined restriction of thiamin, riboflavin, and vitamins B-6 and C with supplementation of other vitamins at twice the RDA.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group with supplementation of twice the RDA of all vitamins.
Number of subjects: 23
Study: 31715039

Group type: EXPERIMENTAL
Intervention: Virtual reality intervention
Number of subjects: 136

Group type: COMPARATOR
Intervention: Routine intravenous injection procedure
Number of subjects: 136
Study: 31044363

Group type: EXPERIMENTAL
Intervention: Fractional micro-needle radiofrequency (FMR)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Fractional CO2 laser
Number of subjects: 17
Study: 29267737

Group type: EXPERIMENTAL
Intervention: Group education intervention
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 183
Study: 26518955

Group type: EXPERIMENTAL
Intervention: L-alanyl-glutamine (50 g)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 33
Study: 24617168

Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg and placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ginger 750 mg and placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ginger 750 mg and Diclofenac 50 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21566876

Group type: EXPERIMENTAL
Intervention: Case-based learning (CBL) group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional group (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CBL group
Number of subjects: 60
Study: 19571249

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 3320

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 3320
Study: 17052502

Group type: EXPERIMENTAL
Intervention: Bortezomib (Velcade) treatment
Number of subjects: 47
Study: 14727011

Group type: EXPERIMENTAL
Intervention: Continuous oral daily ibandronate (2.5 mg/day)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Intermittent oral ibandronate (20 mg every other day for 12 doses every 3 months)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 11518354

Group type: EXPERIMENTAL
Intervention: Disodium clodronate (300 mg to 900 mg intravenously)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (intravenously)
Number of subjects: 10
Study: 9590668

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 7825990

Group type: EXPERIMENTAL
Intervention: PRP-T at 1 and 3 months (group A)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: PRP-T at 2 and 4 months (group B)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: PRP-T in lyophilized form at 2, 3 and 4 months (second study)
Number of subjects: 197

Group type: COMPARATOR
Intervention: No PRP-T (group C)
Number of subjects: 197
Study: 2970805

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF, 99‐126) infusion at 15 ng.kg‐1.min‐1 for 20 minutes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 10
Study: 30185428

Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy‐Health Care
Number of subjects: 167

Group type: COMPARATOR
Intervention: Attention control (weekly family supportive counseling)
Number of subjects: 167
Study: 28780562

Group type: EXPERIMENTAL
Intervention: Adipose graft transposition procedure (AGTP)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard clinical practice
Number of subjects: 108
Study: 26637169

Group type: EXPERIMENTAL
Intervention: Multi-faceted strategy including feedback, educational sessions, reminders, and additional/optional improvement actions
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Competitive feedback strategy (providing non-anonymous comparative feedback on appropriateness of antibiotic use)
Number of subjects: 50
Study: 22968306

Group type: EXPERIMENTAL
Intervention: Protein supplementation (15 g·d‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21362032

Group type: EXPERIMENTAL
Intervention: Omeprazole plus melatonin (group B)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Omeprazole plus tryptophan (group C)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Omeprazole plus placebo (group A)
Number of subjects: 42
Study: 18781069

Group type: EXPERIMENTAL
Intervention: Calcium pre-rinse followed by a 228 microg/g F rinse
Number of subjects: 12

Group type: COMPARATOR
Intervention: 912 microg/g F rinse
Number of subjects: 12

Group type: COMPARATOR
Intervention: 228 microg/g F rinse
Number of subjects: 12
Study: 17161060

Group type: EXPERIMENTAL
Intervention: s.c. beta-EPO for 3 months twice weekly, in addition to daily oral iron
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline in s.c. injections and daily oral iron
Number of subjects: 40
Study: 14616408

Group type: EXPERIMENTAL
Intervention: Voriconazole 3 mg kg‐1 twice daily
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Voriconazole (various doses)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 11771972

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study: 9565125

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine, 60 mg intravenously at the time of trocar insertion
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ibuprofen, 800 mg orally an hour before surgery
Number of subjects: 70
Study: 8033760

Group type: EXPERIMENTAL
Intervention: Vapor from essential oil of black pepper
Number of subjects: 48

Group type: COMPARATOR
Intervention: Mint/menthol cartridge
Number of subjects: 48

Group type: COMPARATOR
Intervention: Empty cartridge (unflavored placebo)
Number of subjects: 48
Study: 2548964

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (50-80 mg/kg/day in three doses during meals)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Co-trimoxazole (6-10 mg trimethoprim/kg/day in two doses after meals)
Number of subjects: 55
Study: 7576

Group type: COMPARATOR
Intervention: Propranolol alone (80 to 160 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combined propranolol (80 to 160 mg) and phenoxybenzamine (20 to 50 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combined therapy with hydrochlorothiazide (50-100 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combined therapy with hydrochlorothiazide
Number of subjects: 17
Study: 31487868

Group type: EXPERIMENTAL
Intervention: Medical condition (food addiction diagnosed by a doctor)
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Self-diagnosed condition (target believes herself to be a food addict)
Number of subjects: 962

Group type: COMPARATOR
Intervention: Control condition (no reference to food addiction)
Number of subjects: 962
Study: 29155873

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 0
Study: 26417835

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide (BNP)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: C-type natriuretic peptide (CNP)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 6
Study: 23292595

Group type: EXPERIMENTAL
Intervention: Active anodal tDCS
Number of subjects: 3

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 3
Study: 21673660

Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (CP) - oral metronomic dosing (50 mg/day)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (CP) - single intravenous dose (1,000 mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (CP) - both oral and intravenous
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group - virus only (N = 8)
Number of subjects: 35
Study: 17507163

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg (P600)
Number of subjects: 91
Study: 17183151

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Pravastatin (80 mg/day)
Number of subjects: 23
Study: 12845210

Group type: EXPERIMENTAL
Intervention: Raltitrexed 3.0 mg/m² and oxaliplatin 130 mg/m² intravenously on day 1 every 3 weeks
Number of subjects: 21